RCM
BCAX

RA Capital Management’s Bicara Therapeutics BCAX Stock Holding History

RA Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$144M Buy
7,255,993
+300,000
+4% +$5.16M 1.53% 17
2025
Q4 		$117M Hold
6,955,993
– – 1.2% 20
2025
Q3 		$110M Hold
6,955,993
– – 1.35% 18
2025
Q2 		$64.6M Hold
6,955,993
– – 1.09% 23
2025
Q1 		$90.6M Hold
6,955,993
– – 1.51% 19
2024
Q4 		$121M Hold
6,955,993
– – 1.61% 15
2024
Q3 		$177M Buy
+6,955,993
New +$177M 2.04% 13

Other funds holding BCAX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM

RA Capital Management's BCAX Position: Q1 2026 in Review

RA Capital Management increased its Bicara Therapeutics (BCAX) stake by 4.3% in Q1 2026, buying an estimated $5.16M and bringing the position to 7,255,993 shares worth $144M. The position accounts for 1.53% of the portfolio, ranked #17.

RA Capital Management first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $177M in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • RA Capital Management held 7,255,993 shares of Bicara Therapeutics worth $144M as of Q1 2026.
  • RA Capital Management bought 300,000 Bicara Therapeutics shares in Q1 2026, an estimated $5.16M.
  • Bicara Therapeutics made up 1.53% of RA Capital Management's portfolio in Q1 2026, its #17 holding.
  • RA Capital Management first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • RA Capital Management's Bicara Therapeutics position peaked at $177M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.